The closing price of RAPT Therapeutics Inc (NASDAQ: RAPT) was $8.45 for the day, down -5.90% from the previous closing price of $8.98. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 564723 shares were traded.
Ratios:
Our analysis of RAPT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.41 and its Current Ratio is at 7.41. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 22, 2024, Downgraded its rating to Neutral and sets its target price to $10 from $61 previously.
On February 21, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $42 to $10.
JP Morgan Downgraded its Overweight to Neutral on February 21, 2024, whereas the target price for the stock was revised from $35 to $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 05 ’24 when Brockstedt Dirk G. sold 898 shares for $22.78 per share. The transaction valued at 20,456 led to the insider holds 27,820 shares of the business.
HO WILLIAM sold 2,500 shares of RAPT for $54,200 on Dec 21 ’23. The Chief Medical Officer now owns 15,020 shares after completing the transaction at $21.68 per share. On Nov 28 ’23, another insider, HO WILLIAM, who serves as the Chief Medical Officer of the company, sold 1,500 shares for $13.72 each. As a result, the insider received 20,580 and left with 17,520 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RAPT now has a Market Capitalization of 294.04M and an Enterprise Value of 142.08M. Its current Enterprise Value per Revenue stands at 677.37 whereas that against EBITDA is -1.13.
Stock Price History:
Over the past 52 weeks, RAPT has reached a high of $27.35, while it has fallen to a 52-week low of $6.86. The 50-Day Moving Average of the stock is 15.34, while the 200-Day Moving Average is calculated to be 17.83.
Shares Statistics:
RAPT traded an average of 1.25M shares per day over the past three months and 779.8k shares per day over the past ten days. A total of 34.40M shares are outstanding, with a floating share count of 30.59M. Insiders hold about 12.10% of the company’s shares, while institutions hold 90.67% stake in the company. Shares short for RAPT as of Mar 15, 2024 were 3.3M with a Short Ratio of 2.63, compared to 3.51M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.48% and a Short% of Float of 12.79%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.81 for the current quarter, with a high estimate of -$0.72 and a low estimate of -$0.88, while EPS last year was -$0.76. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.68 and low estimates of -$0.88.
Analysts are recommending an EPS of between -$2.54 and -$3.56 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$2.69, with 6 analysts recommending between -$1.57 and -$3.69.
